Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key updates from Maui Derm NP+PA Fall 2024 in Nashville.

A study shows secukinumab clears skin lesions faster than ustekinumab in generalized pustular psoriasis, with improved responses observed by week 2.

A review of 5 highly anticipated FDA decisions expected by year-end, including acoramidis for ATTR-CM, olezarsen for FCS, sotagliflozin for T1D and CKD, and more.

Study findings highlight the individual and combined impact of smoking tobacco and drinking alcohol on achieving PASI75 after 8 weeks of treatment.

The approval is based on findings from BLUE-C, where Cologuard Plus demonstrated sensitivities of 95% for colorectal cancer and 43% for advanced precancerous lesions at 94% specificity.

An EADV 2024 study suggests dupilumab use during pregnancy is generally safe and may lower risks of preterm labor, gestational hypertension, and diabetes.

Crisugabalin at 40 mg/d or 80 mg/d significantly reduced daily pain in adults with postherpetic neuralgia, a phase 3 study found.

Further research is needed to understand the mechanism behind the link as antibiotic exposure is often necessary in care.

A small percentage of participants with psoriasis reported adequate adherence, with nearly half showing low adherence to phototherapy treatment.

These 28-week data on twice-daily ESK-001 highlight the drug’s safety and efficacy among patients with psoriasis.

Contrary to previous research, findings suggest no significant difference in infertility between patients with HS, other dermatological diseases, and healthy controls.

Compared with participants who gained weight or who weight remained stable, the risk of developing gout fell with increased weight loss over 1 year.

An elevated social vulnerability index score was linked to increased mortality among patients with SCD in the 5-year CDC WONDER database.

These data were presented at EADV 2024 by UCB, with presenters highlighting positive long-term efficacy findings for bimekizumab among patients with plaque psoriasis.

Triptans, including eletriptan and sumatriptan, offer better migraine relief than newer, more expensive drugs, suggesting they should be first-line treatments.

Gross hematuria after COVID-19 mRNA vaccination was more likely in females, patients with IgAN/IgAV, and after the second and third vaccine doses.

Taher Modarressi, MD, sits down with hosts to share tips and practical nuggets for cardiometabolic health specialists to optimize prescription and adherence to newer therapies.

The all-optical PAT scanner reduces acquisition time from minutes to seconds and can visualize microvasculature changes to depths approaching 15 mm.

The resubmission includes positive data from a recently completed dry eye disease symptom trial requested by the FDA after a review of the previous NDA.

Individuals with comorbid asthma and food allergies saw no loss of efficacy in this post hoc analysis, suggesting omalizumab’s potential for such patients.

A study reveals that individuals with schizophrenia spectrum disorders experience high rates of comorbid mental health conditions and receive minimally adequate treatment.

This month in review spotlights recent GI pipeline news, new research about IBS and other gastroenterological conditions, and coverage from the 2024 GHAPP conference.

More research is needed to investigate changing trends at presentation and help to inform current treatment strategies.

An analysis of NYC’s lead registry data from 2005 to 2019 revealed a potential association between sickle cell disease and childhood lead poisoning.

The phase 3b/4 findings from PSORIATYK SCALP suggest that oral deucravacitinib led to significant improvements for patients with scalp psoriasis.